Verici Dx (LSE:VRCI) has entered into an agreement with Blue Cross and Blue Shield of Illinois that adds its Tutivia™ post-kidney transplant diagnostic test as an in-network covered service. The arrangement simplifies the reimbursement process and allows eligible patients to access the test at in-network rates across multiple Blue Cross and Blue Shield (BCBS) insurance programmes in Illinois, including commercial plans, managed Medicaid and Medicare Advantage.
The agreement also enables Verici Dx to join the BCBS Preferred Provider Organization network, potentially widening the company’s access to additional BCBS organisations, including those operating in Texas, as well as the wider BCBS Association network covering 33 member plans. Management believes the partnership could substantially expand patient access while helping to streamline the company’s engagement with additional insurance providers, supporting the ongoing commercial rollout of Tutivia.
From a strategic standpoint, the agreement represents a significant step in Verici Dx’s US market expansion and payer coverage growth strategy. However, the company continues to face financial headwinds, including profitability and cash flow challenges, which remain key risk factors despite encouraging corporate developments and favourable technical trading signals. Valuation metrics also remain constrained by ongoing losses.
More about Verici Dx Plc
Verici Dx plc is a precision diagnostics company focused on improving outcomes for organ transplant patients. The company integrates multiomic analysis with proprietary artificial intelligence technologies to develop advanced clinical diagnostic tests that support treatment optimisation, biopsy decision-making and patient risk assessment. Its lead product, Tutivia™, is designed to enable early detection of acute rejection in kidney transplant recipients. Verici Dx operates across laboratory and data science platforms, with headquarters in Cardiff, UK, and Franklin, Tennessee, US.
Leave a Reply